RT Journal Article
SR Electronic
T1 A role for Nucleocapsid-specific antibody function in Covid-19 Convalescent plasma therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.19.22271230
DO 10.1101/2022.02.19.22271230
A1 Jonathan D. Herman
A1 Chuangqi Wang
A1 John Stephen Burke
A1 Yonatan Zur
A1 Hacheming Compere
A1 Jaewon Kang
A1 Ryan Macvicar
A1 Sally Shin
A1 Ian Frank
A1 Don Siegel
A1 Pablo Tebas
A1 Grace H. Choi
A1 Pamela A. Shaw
A1 Hyunah Yoon
A1 Liise-anne Pirofski
A1 Boris Juelg
A1 Katharine J. Bar
A1 Douglas Lauffenburger
A1 Galit Alter
YR 2022
UL http://medrxiv.org/content/early/2022/02/22/2022.02.19.22271230.abstract
AB COVID-19 convalescent plasma (CCP), a passive polyclonal antibody therapeutic, has exhibited mixed results in the treatment of COVID-19. Given that the therapeutic effect of CCP may extend beyond the ability of SARS-CoV-2-specific antibody binding and neutralization to influence the evolution of the endogenous antibody response, we took a systematic and comprehensive approach to analyze SARS-CoV-2 functional antibody profiles of participants in a randomized controlled trial of CCP treatment of individuals hospitalized with COVID-19 pneumonia where CCP was associated with both decreased mortality and improved clinical severity. Using systems serology, we found that the clinical benefit of CCP is related to a shift towards reduced inflammatory Spike (S) responses and enhanced Nucleocapsid (N) humoral responses. We found CCP had the greatest clinical benefit in participants with low pre-existing anti-SARS-CoV-2 antibody function, rather than S or N antibody levels or participant demographic features. Further, CCP induced immunomodulatory changes to recipient humoral profiles persisted for at least two months, marked by the selective evolution of anti-inflammatory Fc-glycan profiles and persistently expanded nucleocapsid-specific humoral immunity following CCP therapy. Together, our findings identify a novel mechanism of action of CCP, suggest optimal patient characteristics for CCP treatment, identify long-last immunomodulatory effects of CCP, and provide guidance for development of novel N-focused antibody therapeutics for severe COVID-19 hyperinflammation.Competing Interest StatementG. A. is a founder of SeromYx Systems, Inc. and an equity holder in Leyden Labs. G.A. is a member of the scientific advisory board of Sanofi Pasteur. The other authors declare no competing interests.Clinical TrialNCT04397757Funding StatementThis study was supported by Nancy Zimmerman, Mark and Lisa Schwartz, an anonymous donor (financial support), Terry and Susan Ragon, the SAMANA Kay MGH Research Scholars award, the Ragon Institute of MGH, MIT and Harvard, the Massachusetts Consortium on Pathogen Readiness (MassCPR), the NIH (3R37AI08028911S1, R01AI146785, U19AI4279001, U19AI135995-02, U19AI4279001, 1U01CA26047601, CIVIC75N93019C00052, T32 AI007061), the Gates Foundation, the Global Health Vaccine Accelerator Platform funding (OPP1146996 and INV001650), and the Musk Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The clinical trial included in this work was approved by the University of Pennsylvania IRB. Secondary use of the samples was approved by the MassGeneral Brigham IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.